The majority of gastrointestinal stromal tumors is characterized by oncogenically activating mutations of the KIT receptor tyrosine kinase and can hence successfully be treated with the KIT inhibitor imatinib mesylate. Here, KIT is linked to gastrointestinal stromal tumor.